Medical Patent News

RSS

Uroplasty announces newly-issued patent for Urgent PC Neuromodulation System

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, announced today the issuance of United States Patent No. 7,668,598 covering the stimulation method used in the Urgent® PC Neuromodulation System.

23 Mar 2010

Covidien subsidiary wins patent infringement suit against Applied Medical Resources

Covidien, a leading global provider of healthcare products, today announced that a subsidiary of the Company won a patent infringement suit against Applied Medical Resources Corporation relating to certain of Applied Medical’s Kii™ and Universal® laparoscopic trocars.

23 Mar 2010

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

Can-Fite BioPharma Ltd, a biopharmaceutical company, traded on the TASE and developing anti- inflammatory and anti-cancer drugs, announced today the filing of a patent application, in conjunction with the United Stated National Institutes of Health (NIH), for the treatment of Uveitis with its A3 adenosine receptor ligands.

23 Mar 2010

Drug company fights for patent extension

The New York Times: The drug maker Medicines Company that makes the blood thinner called Angiomax, missed the application deadline to extend its patent back in 2000 by a day or two, depending on how you count.

20 Mar 2010

Providence receives U.S. patent for CPMMS

Providence today announces the receipt of a United States Patent for the Comprehensive Particulate Matter Measurement System (CPMMS) and the Methodology for its Use. Yousheng Zeng, PhD, PE, a principal of Providence, is the inventor of this system. Dr. Zeng explains, "Unlike current methods of monitoring air-borne particulate matter (PM), the CPMMS monitors the portion of PM that can reach and deposit in a human respiratory system."

19 Mar 2010

USPTO reissues composition of matter patent for Poniard Pharmaceuticals' picoplatin

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced that the U.S. Patent & Trademark Office has granted and will reissue the composition of matter patent for picoplatin as RE41209, replacing USPN 5,665,771 ('771 patent), on April 6, 2010. The reissue was applied for May 8, 2009, and, on March 17, 2010, the USPTO released the "Issue Notification" for the reissue application.

19 Mar 2010

StemCells granted UK patent covering true rat stem cells and genetically engineered rats

StemCells, Inc. announced today that the United Kingdom (UK) Intellectual Property Office has granted patent number GB2451523 with broad claims covering true (germline competent) rat stem cells and genetically engineered rats derived from these cells. The patented technology is expected to have significant utility to academic and pharmaceutical industry researchers by enabling them to create novel rat models for the study of human diseases. Both mice and rats are used by scientists to model various human diseases.

18 Mar 2010

USPTO allows Regulus Therapeutics' claims covering methods of antagonizing miR-181a for regulating immune response

Regulus Therapeutics Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed claims in U.S. Application Serial No. 11/977,506 covering methods of antagonizing miR-181a to regulate immune response. This patent is owned by Stanford University and licensed exclusively to Regulus. miR-181a has been shown to regulate the response of immune cells, such as T lymphocytes, to specific stimuli and modulation of miR-181a could lead to a novel treatment of inflammatory disease.

18 Mar 2010

Bone Biologics receives Notice of Allowance of patent claims that protects formation of cartilage by UCB-1

Bone Biologics, Inc. announced today that it has received a US Patent Office Notice of Allowance of patent claims which strongly protects the formation of cartilage by the unique NELL 1 protein (UCB-1). Additional claims cover the surgical application of the NELL 1 (UCB-1) protein by several delivery agents.

18 Mar 2010

ImmunoCellular Therapeutics receives Notice of Allowance covering antibodies targeting pancreatic cancer

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance from the United States Patent and Trademark Office covering technology relating to monoclonal antibodies that bind to certain epitopes present on pancreatic cancers. This patent will broaden the Company’s proprietary intellectual property for ICT-109 and ICT-37, two of the Company’s monoclonal antibody product candidates.

17 Mar 2010

Patent applications continue to alter medical landscape to improve patient care

Over the past 40 years, more than 2,400 patents and patent applications-pioneering modern medicine with the devices and drugs that advance minimally invasive treatments-have been filed by members of the Society of Interventional Radiology.

17 Mar 2010

Shire receives Paragraph IV Notice Letter over generic INTUNIV ANDAs from Teva Pharmaceuticals

Shire plc, announces that it has received a Paragraph IV Notice Letter from Teva Pharmaceuticals USA, Inc. advising of the filing of an Abbreviated New Drug Application for a generic version of Shire's 1 mg, 2mg, 3 mg, and 4mg guanfacine hydrochloride extended release tablets, INTUNIV(TM).

17 Mar 2010

USPTO issues Notice of Allowance for Quick-Med Technologies' NIMBUS technology

Quick-Med Technologies, Inc., a leader in developing innovative antimicrobial technologies for the healthcare and consumer markets, announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance for intellectual property that significantly adds to the current patent coverage for the Company's NIMBUS technology.

17 Mar 2010

Actoplus Met and Actos: Mylan enters into settlement agreements with Takeda Pharmaceutical

Mylan Inc. today announced that it has entered into settlement agreements with Takeda Pharmaceutical Co. related to two treatments for type 2 diabetes: Actoplus Met®, 15 mg/500 mg and 15 mg/850 mg, known generically as Pioglitazone Hydrochloride (HCl) and Metformin HCl Tablets, and Actos®, 15 mg, 30 mg and 45 mg, known generically as Pioglitazone HCl Tablets.

16 Mar 2010

Epeius Biotechnologies' tumor-targeted vaccine technology for cancer immunotherapy receives patent protection

Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for a crucial patent covering its leading tumor-targeted vaccine technology for cancer immunotherapy. The issuance of this valuable patent protection for tumor targeted immunotherapy follows on the heels of two international patents covering targeted gene medicine in the U.S. and Europe, respectively, and places Epeius Biotech at the forefront of these emerging fields of clinical medicine with best-of-breed solutions and incontrovertible proofs-of-principle in the clinic.

16 Mar 2010

AlloSource receives US patent for cleaning and disinfecting system

AlloSource, one of the nation's largest non-profit providers of skin, bone and soft tissue allografts for use in surgical procedures and the world's largest processor of live cellular bone growth substitutes, has been awarded its first patent for a propriety tissue cleaning and disinfecting process called RICA.

16 Mar 2010

Impax Laboratories initiates challenge of patent over generic TRILIPIX

Impax Laboratories, Inc. today confirms that it has initiated a challenge of the patent listed by Abbott Laboratories and Fournier Laboratories Ireland Ltd. in connection with its TRILIPIX® (choline fenofibrate) delayed-release capsules, 135 mg and 45 mg.

15 Mar 2010

Ranbaxy resolves generic Actos patent litigation

Ranbaxy Laboratories Limited, along with its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc. (collectively, "Ranbaxy"), announced today that they have reached an agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Ranbaxy's generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15 mg, 30 mg and 45 mg tablets.

15 Mar 2010

Neurologix receives US PTO Notice of Allowance concerning treatment approach for epilepsy

Neurologix, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for intellectual property central to the company’s approach to the treatment of epilepsy. The patent allowance specifically refers to Neurologix’s patent application, “Methods and Compositions for the Treatment of Neurological Disease,” which covers the treatment of seizures associated with temporal lobe epilepsy by direct administration into the brain’s temporal lobe of an AAV vector encoding Neuropeptide Y (NPY).

15 Mar 2010

Generic Focalin XR patent suit: Intellipharmaceutics International announces settlement

Intellipharmaceutics International Inc. today announced that Novartis Pharmaceuticals Corporation and Celgene Corporation have settled their patent suit in the U.S. District Court for the District of New Jersey, and Elan Pharma International Ltd. has settled its patent suit in the U.S. District Court for the District of Delaware, with Intellipharmaceutics Corp., a wholly-owned subsidiary of Intellipharmaceutics International, and its licensee Par Pharmaceutical, Inc. over a generic version of the Attention Deficit Hyperactivity Disorder drug Focalin XR® (dexmethylphenidate hydrochloride).

12 Mar 2010

Medical Patent News

Uroplasty announces newly-issued patent for Urgent PC Neuromodulation System

Covidien subsidiary wins patent infringement suit against Applied Medical Resources

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

Drug company fights for patent extension

Providence receives U.S. patent for CPMMS

USPTO reissues composition of matter patent for Poniard Pharmaceuticals' picoplatin

StemCells granted UK patent covering true rat stem cells and genetically engineered rats

USPTO allows Regulus Therapeutics' claims covering methods of antagonizing miR-181a for regulating immune response

Bone Biologics receives Notice of Allowance of patent claims that protects formation of cartilage by UCB-1

ImmunoCellular Therapeutics receives Notice of Allowance covering antibodies targeting pancreatic cancer

Patent applications continue to alter medical landscape to improve patient care

Shire receives Paragraph IV Notice Letter over generic INTUNIV ANDAs from Teva Pharmaceuticals

USPTO issues Notice of Allowance for Quick-Med Technologies' NIMBUS technology

Actoplus Met and Actos: Mylan enters into settlement agreements with Takeda Pharmaceutical

Epeius Biotechnologies' tumor-targeted vaccine technology for cancer immunotherapy receives patent protection

AlloSource receives US patent for cleaning and disinfecting system

Impax Laboratories initiates challenge of patent over generic TRILIPIX

Ranbaxy resolves generic Actos patent litigation

Neurologix receives US PTO Notice of Allowance concerning treatment approach for epilepsy

Generic Focalin XR patent suit: Intellipharmaceutics International announces settlement

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Latest News